@article{126db2ee9db841e4a8126cbd2e606540,
title = "Immune checkpoint inhibitor-induced sarcoidosis-like granulomas",
abstract = "Immune checkpoint inhibitors targeting the cytotoxic T lymphocyte-associated antigen-4 and programmed cell death-1 receptors have transformed the treatment of melanoma and other cancers. These therapies are associated with a number of side effects, including immune-related adverse events. Sarcoidosis-like granulomas (SLGs) are important immune checkpoint inhibitor-related reactions to recognize as SLGs can mimic disease progression and accordingly impact treatment decisions. We systematically review reports of immune checkpoint inhibitor-induced SLGs in cancer patients and discuss potential underlying pathophysiological mechanisms.",
keywords = "CTLA-4, Drug reactions, Immune checkpoint inhibitor, Melanoma, PD-1, Sarcoidosis-like granuloma",
author = "Rambhia, {Pooja H.} and Barbara Reichert and Scott, {Jeffrey F.} and Feneran, {Ashley N.} and Kazakov, {Jordan A.} and Kord Honda and Henry Koon and Gerstenblith, {Meg R.}",
note = "Funding Information: This study was funded by the Char and Chuck Fowler Foundation, RES119774. Funding Information: Author PHR declares that she has no conflict of interest. Author BR declares that she has no conflict of interest. Author JFS declares that he has no conflict of interest. Author ANF declares that she has no conflict of interest. Author JAK declares that he has no conflict of interest. Author KH declares that he has no conflict of interest. Author HK owns stock in Company BMS. Author MRG has received research grants from the Char and Chuck Fowler Family Foundation. Publisher Copyright: {\textcopyright} 2019, Japan Society of Clinical Oncology.",
year = "2019",
month = oct,
day = "1",
doi = "10.1007/s10147-019-01490-2",
language = "English (US)",
volume = "24",
pages = "1171--1181",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "10",
}